G De Hertogh

Relationship of efficacy with <i>KRAS</i> status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data)

Sabine Tejpar, Marc Peeters, Yves Humblet et al. · Journal of Clinical Oncology · 2008 · 92 citations

Medicine, Oncology, Pharmacology +17

KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab

Wendy De Roock, Joris De Schutter, G De Hertogh et al. · Journal of Clinical Oncology · 2007 · 21 citations

Medicine, Oncology, Pharmacology +17

Analysis of HER2 expression and gene amplification in adenocarcinoma of the stomach and the gastro-oesophageal junction: rationale for the Belgian way of working.

Anne Jouret‐Mourin, Anne Hoorens, G De Hertogh et al. · PubMed · 2012 · 12 citations

Medicine, Oncology, Pathology +17